Why it matters: Apixaban is metabolized mainly by CYP3A4 and transported by P-gp, making it vulnerable to interactions that can increase bleeding or reduce effectiveness. Real-world danger: A patient ...

For patients with HIV and atrial fibrillation, this study found that apixaban was associated with less bleeding when compared with warfarin and rivaroxaban. Data remain inconclusive regarding ...

Apixaban and rivaroxaban are the oral anticoagulants most frequently used to treat acute venous thromboembolism. However, uncertainty remains about the difference in bleeding risk between the two ...

As patients navigate the intersection of cardiovascular, mental, and women's health needs, staying current with medication label updates is no longer optional—it's a critical part of safe care ...

The use of apixaban (Eliquis; Bristol-Myers Squibb) over rivaroxaban (Xarelto; Bayer/Janssen) in patients with atrial fibrillation (AF) and valvular heart disease is associated with better clinical ...

Please provide your email address to receive an email when new articles are posted on . Continued anticoagulation is recommended for patients with active cancer and/or ongoing cancer treatment.

Please provide your email address to receive an email when new articles are posted on . Treatment of venous thromboembolism with apixaban was tied to lower bleeding risk vs. rivaroxaban. Adherence to ...